Patents by Inventor Gourab Bhattacharjee

Gourab Bhattacharjee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for modulating kallikrein (KLKB1) expression
    Patent number: 9322021
    Abstract: Disclosed herein are methods for decreasing kallikrein and treating or preventing thromboembolic conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to kallikrein include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Methods for inhibiting kallikrein can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: April 26, 2016
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Alexey Revenko, Gourab Bhattacharjee, Robert A. MacLeod
  • Methods for modulating kallikrein (KLKB1) expression
    Patent number: 9315811
    Abstract: Disclosed herein are methods for decreasing kallikrein and treating or preventing inflammatory conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to kallikrein include hereditary angioedema (HAE). Methods for inhibiting kallikrein can also be used as a prophylactic treatment to prevent individuals at risk for developing an inflammatory condition, such as, hereditary angioedema.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: April 19, 2016
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Gourab Bhattacharjee, Alexey Revenko, Robert A. MacLeod
  • Methods for modulating factor 12 expression
    Patent number: 9187749
    Abstract: Disclosed herein are methods for decreasing Factor 12 and treating or preventing inflammatory conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 12 include hereditary angioedema (HAE). Methods for inhibiting Factor 12 can also be used as a prophylactic treatment to prevent individuals at risk for developing an inflammatory condition, such as, hereditary angioedema.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: November 17, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Gourab Bhattacharjee, Alexey Revenko, Robert A. MacLeod
  • METHODS FOR MODULATING FACTOR 12 EXPRESSION
    Publication number: 20140228300
    Abstract: Disclosed herein are methods for decreasing Factor 12 and treating or preventing inflammatory conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 12 include hereditary angioedema (HAE). Methods for inhibiting Factor 12 can also be used as a prophylactic treatment to prevent individuals at risk for developing an inflammatory condition, such as, hereditary angioedema.
    Type: Application
    Filed: June 8, 2012
    Publication date: August 14, 2014
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Gourab Bhattacharjee, Alexey Revenko, Robert A. MacLeod
  • METHODS FOR MODULATING KALLIKREIN (KLKB1) EXPRESSION
    Publication number: 20140213631
    Abstract: Disclosed herein are methods for decreasing kallikrein and treating or preventing inflammatory conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to kallikrein include hereditary angioedema (HAE). Methods for inhibiting kallikrein can also be used as a prophylactic treatment to prevent individuals at risk for developing an inflammatory condition, such as, hereditary angioedema.
    Type: Application
    Filed: June 8, 2012
    Publication date: July 31, 2014
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Gourab Bhattacharjee, Alexey Revenko, Robert A. MacLeod
  • METHODS FOR MODULATING KALLIKREIN (KLKB1) EXPRESSION
    Publication number: 20140206745
    Abstract: Disclosed herein are methods for decreasing kallikrein and treating or preventing thromboembolic conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to kallikrein include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Methods for inhibiting kallikrein can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.
    Type: Application
    Filed: June 29, 2012
    Publication date: July 24, 2014
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Alexey Revenko, Gourab Bhattacharjee, Robert A MacLeod